Top Research Reports For Celgene, Ford & Dow Chemical

Tuesday, November 2, 2016

Today's Research Daily features new research reports on 16 major stocks, including Dow Chemical (NYSE:DOW), Celgene (NASDAQ:CELG), and Ford (F).

Dow Chemical shares have lagged the basic materials sector this year, but have performed largely in-line with the S&P 500 index. The company's third-quarter results exceeded expectations, aided by its productivity and cost-reduction actions. The analyst likes Dow’s productivity and aggressive portfolio management actions as well as strategic investments in the U.S. Gulf Coast and the Middle East. The company is also moving forward with its planned mega-merger with DuPont (NYSE:DD), which is expected to create significant synergies. Dow should also gain from cost synergies associated with Dow Corning Silicones business in 2016. (You can read the full research report on Dow Chemical here>>)

Buy rated Celgene shares have been laggards this year, as have been other drug makers given ongoing questions about pricing issues and other regulatory uncertainties. These issues notwithstanding, Celgene’s third-quarter results were better than expected with the company beating on both top- and bottom-line estimates. Multiple myeloma drug Revlimid continued to grow on the back of market share gains and increased duration. The analyst likes Celgene’s ongoing label expansion efforts and pipeline development. The company anticipates several pipeline-related events over the upcoming quarters and next few years. Celgene’s raised and updated its expectations for both 2016 and 2017, are also encouraging. (You can read the full research report on Celgene here>>)

Ford's Q3 results came in better than expected, but expectations were low given management's negative guidance following the June quarter report. The stock stands out for its underperformance - it has lagged GM, the broader auto space as well as the S&P 500 (down more than 17% year to date). The automaker's full-year 2016 pre-tax profit, adjusted earnings per share and automotive operating margin to be lower than 2015. Further, results from most regions are expected to be weaker this year. In the updated research report issued today, the analyst discusses the pros & cons of investing in Ford shares at present. Of the positives in the Ford story, the analyst points out Ford’s product launches, global expansion plans, efficient capital deployment, success of the One Ford plan, focus on autonomous vehicle development and solid long-term outlook. But Ford expects 2016 (You can read the full research report on Ford here>>)

Other noteworthy reports we are featuring today include Alexion (ALXN), BB&T Corp (NYSE:BBT) and Sony (SNE).

Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>